93196-4

LOINC code 93196-4 identifies "Warfarin response genotype panel - Blood or Tissue by Molecular genetics method". This panel contains genotype results for warfarin dosing. As of 2019, CYP2C9, VKORC1, CYP4F2, and rs12777823 genotypes are used when available to help determine a patient's initial therapeutic warfarin dose. VKORC1 and CYP2C9 genotypes are the most important genetic determinants of warfarin dosing. Additionally, a genetic variation in the CYP4F2 gene, CYP4F2*3, as well as a variant near the CYP2C gene cluster, rs12777823, have been associated with influencing warfarin therapy.[NCBI Books: NBK84174] This panel is based on, but not limited in use to, the 2017 Update of the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing, which provides warfarin dosing recommendations for adults with and without African ancestry, and also for pediatric patients.[https://cpicpgx.org/content/guideline/publication/warfarin/2017/warfarin.pdf]

This code measures Warfarin response genotype panel in Bld/Tiss. It belongs to the PANEL.MOLPATH.PHARMG class in the LOINC classification.

LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.